Mekel Haunsby @Luma_25000: "Yesterday my largest holding by..."

Denmark

Yesterday my largest holding by share count – 1,500 shares of $HUMA (Humacyte Inc) – moved ~30% in a single session! 😎 Big move, bravo! ❌ But: No, I did not sell or rebalance... Here’s the full context – including how this fits into my broader portfolio logic. 🎯 Rebalancing framework (rules first) For every non-core holding I define explicit sell / trim levels in advance. $HUMA has not reached its first sell-off point yet. Selling here would be emotional rebalancing, not disciplined execution. 🌊 Volatility – relative, not absolute $HUMA is volatile, yes – but context matters. 📉 Compared to $SPX500 $HUMA obviously swings far more. But even “safe” mega caps can move violently when expectations reset. 🧠 Example: $NVO (Novo-Nordisk A/S SPONS ADR) Years ago I used to have more than 50% of my portfolio in Novo Nordisk. I exited that position around ~$100 per share when risk/reward shifted. That exit wasn’t because $NVO is a bad company – but because upside asymmetry compressed while volatility remained. Big companies can still hurt you if you overstay. 🔄 Capital rotation – not attachment After exiting $NVO, I rotated medical exposure into names where I see much higher upside asymmetry: 👉 $GOSS (Gossamer Bio Inc) 👉 $BMEA (Biomea Fusion Inc) Both are higher risk, yes – but also far earlier in their value curve. That’s intentional. I’m not chasing stability, I’m chasing mispriced outcomes. 📰 What actually drove $HUMA’s move (not hype) Congress approved funding via the FY 2026 U.S. Department of Defense Appropriations Act for: 👉 assessment, procurement, and implementation of FDA-approved biologic vascular repair solutions 👉 targeting traumatic extremity arterial injuries in military personnel This follows the FY2026 National Defense Authorization Act (Dec 2025), explicitly calling for FDA-approved breakthrough vascular repair technologies. 🧬 Product-level validation This directly supports Symvess, which received FDA approval in December 2024. A ready-to-use bioengineered human vessel when a patient’s own vein is unavailable. This is not speculative research funding. This is deployment-level validation. 🏭 Company positioning Humacyte focuses on universally implantable bioengineered human tissues, with pipeline exposure to: 👉 vascular trauma 👉 PAD 👉 dialysis access 👉 advanced tissue constructs Market cap post-move: roughly $200–230M. 📊 Financial reality (transparent) Yes, the financials are ugly: 👉 revenue ~$1.57M 👉 operating margin ~-6700% 👉 net margin ~-2300% 👉 Altman Z-score ~-10 👉 beta ~2.9 That’s normal for pre-commercial biotech transitioning into rollout. 💰 What matters more right now 👉 FDA approval secured 👉 manufacturing & delivery lines being built 👉 government endorsement in place 👉 financing secured for a foreseeable runway This is an execution phase – not a margin story yet. 📈 Why I’m holding 👉 Symvess becomes standard of care in military trauma (initial wedge, highest urgency use case) 👉 adoption expands into civilian trauma, where vascular injury volumes are much larger 👉 Symvess gains traction in PAD (peripheral artery disease), a massive chronic market 👉 use cases broaden into dialysis access, where reliable vascular conduits are a key bottleneck 🧬 Beyond Symvess, Humacyte’s platform matters: 👉 Acellular Tissue Engineered Vessels designed to be universally implantable 👉 pipeline leverage into advanced tissue constructs and future organ-support applications 👉 same manufacturing platform reused across multiple indications (scalability upside) 🛡️ Patents / IP angle: 👉 strong patent protection around their bioengineered vessel platform, manufacturing process, and use cases 👉 that IP moat matters if adoption accelerates, because manufacturing know-how + regulatory work is not easy to copy That’s why I see $HUMA as a true 10x–20x asymmetric setup, not a trim-on-first-spike trade. ⚠️ Risk reminder This is high-risk biotech: 👉 dilution risk 👉 execution risk 👉 sharp drawdowns Position sizing and time horizon matter. I’m staying in. Not financial advice. Do your own research.